Trial Profile

IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma a Single-center, Open-label, Phase II Clinical Trial. REPLY Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Parsaclisib (Primary) ; Rituximab (Primary)
Indications Follicular lymphoma; Lymphoma; Marginal zone B-cell lymphoma
Focus Biomarker; Therapeutic Use
Acronyms REPLY

Most Recent Events

19 Feb 2022 Planned primary completion date changed from 31 Oct 2023 to 31 Dec 2023.
13 Oct 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com